← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in cholangiocarcinoma: P26045

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
June 2, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — P26045 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in cholangiocarcinoma.

# Signals Article: Investigating the Putative Target P26045 in Cholangiocarcinoma

Background

The protein encoded by the putative target P26045 has surfaced as a candidate of interest in the study of cholangiocarcinoma, a malignancy arising from the bile ducts. Preliminary expression data suggest that P26045 may play a role in the tumor biology of cholangiocarcinoma, potentially influencing pathways related to tumor growth and metastasis. However, the therapeutic implications of targeting this protein remain largely unexplored, indicating a need for further investigation.

Data-mining rationale

To identify novel therapeutic targets for cholangiocarcinoma, we performed a data-mining analysis using the UniProt database, focusing on reviewed human entries associated with the disease. We cross-referenced these entries against 108 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate P26045 was identified in several expression-profiling studies, yet it currently lacks any registered Phase 1 or higher clinical programs, highlighting a gap in its potential clinical application.

Why prior analyses may have missed this

Many of the GEO datasets included in our analysis were generated prior to the adoption of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The lack of rigorous multiple-testing corrections in earlier studies may have obscured the significance of P26045’s expression patterns in cholangiocarcinoma. Consequently, the relevance of this candidate may not have been fully appreciated, underscoring the need for a re-analysis of existing data using contemporary statistical methodologies.

Reasoning for further validation

To further explore the role of P26045 in cholangiocarcinoma, we propose the following experimental approaches: 1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to accurately identify differentially expressed genes. 2. **Validate the top differentially-expressed genes** through quantitative PCR (qPCR) in an independent cohort of cholangiocarcinoma samples to confirm the expression patterns observed in the initial analysis. 3. **Check tissue specificity** of P26045 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to evaluate its potential as a selective therapeutic target. 4. **Run pathway analysis** using tools like STRING or OmniPath to contextualize P26045 within relevant biological pathways and networks associated with cholangiocarcinoma. 5. **If validated**, assess the druggability of P26045 through databases such as DGIdb and ChEMBL to explore potential therapeutic compounds that may target this candidate.

References

  • [UniProt: P26045](https://www.uniprot.org/uniprot/P26045)
  • [UniProt: Q96IL0](https://www.uniprot.org/uniprot/Q96IL0)
  • [UniProt: O00233](https://www.uniprot.org/uniprot/O00233)
  • [UniProt: P08922](https://www.uniprot.org/uniprot/P08922)
  • [UniProt: Q99102](https://www.uniprot.org/uniprot/Q99102)
  • [GEO Accession: GDS:200277546](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200277546)
  • [GEO Accession: GDS:200319418](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200319418)
  • [GEO Accession: GDS:200277244](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200277244)
  • [GEO Accession: GDS:200285761](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200285761)
  • [GEO Accession: GDS:200255470](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200255470)

References

  1. UniProtKB. Entry P26045. The UniProt Consortium. [link]
  2. UniProtKB. Entry Q96IL0. The UniProt Consortium. [link]
  3. UniProtKB. Entry O00233. The UniProt Consortium. [link]
  4. UniProtKB. Entry P08922. The UniProt Consortium. [link]
  5. UniProtKB. Entry Q99102. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications